Faiz, Alen
Imkamp, Kai
van der Wiel, Erica
Boudewijn, Ilse M.
Koppelman, Gerard H. http://orcid.org/0000-0001-8567-3252
Brandsma, Corry-Anke http://orcid.org/0000-0001-8911-3658
Kerstjens, Huib A. M. http://orcid.org/0000-0001-7705-7927
Timens, Wim http://orcid.org/0000-0002-4146-6363
Vroegop, Sebastiaan
Pasma, Henk R.
Boersma, Wim G.
Wielders, Pascal http://orcid.org/0000-0003-3719-5967
van den Elshout, Frank
Mansour, Khaled
Steiling, Katrina
Spira, Avrum
Lenburg, Marc E.
Heijink, Irene H.
Postma, Dirkje S.
van den Berge, Maarten
Clinical trials referenced in this document:
Documents that mention this clinical trial
Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD
https://doi.org/10.1038/s41598-020-72551-0
Documents that mention this clinical trial
Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD
https://doi.org/10.1038/s41598-020-72551-0
Documents that mention this clinical trial
Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD
https://doi.org/10.1038/s41598-020-72551-0
Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial
https://doi.org/10.1371/journal.pone.0063430
Th2 high and mast cell gene signatures are associated with corticosteroid sensitivity in COPD
https://doi.org/10.1136/thorax-2021-217736
Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial
https://doi.org/10.1371/journal.pone.0143793
Funding for this research was provided by:
Chiesi Farmaceutici
Koninklijke Nederlandse Akademie van Wetenschappen
Stichting Astma Bestrijding
Chiesi Pharmaceuticals B.V.
Article History
Received: 23 November 2018
Accepted: 27 August 2020
First Online: 15 October 2020
Competing interests
: IMB reports fees paid to the University from GlaxoSmithKline. GHK reports institutional grants from the Lung Foundation of the Netherlands, TEVA, GlaxoSmithKline, Ubbo Emmius Foundation, and TETRI Foundation. HAMK reports institutional grants from Novartis, Boehringer Ingelheim, and GlaxoSmithKline; speaking fees from Boehringer Ingelheim; consultant fees from AstraZeneca, Chiesi, GlaxoSmithKline, and Novartis; board membership with Chiesi, GlaxoSmithKline, and Novartis; and institutional patient fees from Fluidda. WT reports fees paid to the University from Pfizer, GlaxoSmithKline, Chiesi, Roche Diagnostics/Ventana, Biotest, Merck Sharp Dohme, Novartis, Lilly Oncology and a grant from the Dutch Asthma Fund. KS has a patent 9,677,138 issued for the Boston University, Annual royalties from UpToDate for co-authoring an UpToDate chaptor on Gene Expression, honoraria from Acdemic Research Coalition LLC for serving as expert faculty member and speaker at annual Respiratory Disease Young Investigators’ Forum, Grant from Lungevity Foundation. MEL reports stock from Metera Pharmaceuticals. DSP reports consultancy fees or research grants paid to the University from AstraZeneca, Chiesi, Genentec, GlaxoSmithKline, Roche. MvdB reports research grants paid to the University from Chiesi, GlaxoSmithKline and TEVA. AF, KI, EvdW, CAB, SV, HRP, WgB, PW, FvdE, KM, AS and IHH have no competing interests.